Phase 3 N=121 Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
Anemia
Primary: Mean Change From Baseline to the Highest Hemoglobin up to Day 71 — 1.3; .7 g/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,050 Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
Chronic Hepatitis c · Cirrhosis, Liver · Fibrosis, Liver
Primary: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase…
Phase 3 N=194 Effect on Weight Loss of Exenatide Versus Placebo
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Body Weight — -6.16; -3.97 kg — p=0.0030
Phase 3 N=1,117 A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
Osteoarthritis, Hip · Osteoarthritis, Knee · Lower Back Pain
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 766; 202 Participants
Phase 3 N=173 Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
Allergic Rhinitis · Chronic Urticaria
Primary: Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR) — -1.5; 1.3 beats per minute
Phase 3 N=321 A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring
Fibromyalgia
Primary: Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4 — -0.9; 4.0; 0.2; 3.7 mm Hg
Phase 3 N=2,446 Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
Overactive Bladder
Primary: Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment). — -1.46; -1.61; -1.72 number of episodes…
Phase 3 N=396 A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
Chronic Bronchitis
Primary: Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population) — 93.0; 94.2; 7.0; 5.8 percent
Phase 3 N=232 Rebif New Formulation (RNF) Quality of Life (QOL) Study
Relapsing Multiple Sclerosis
Primary: Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ) — 5.0 percent change — p=<0.001
Phase 3 N=945 Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Crohn's Disease
Primary: Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5. — 492 Participants
Phase 3 N=212 HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
Infection, Human Immunodeficiency Virus I · HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks — 81; 82; 19; 18 Percentage of participants
Phase 3 N=451 Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes
Type 1 Diabetes
Primary: Change in Glycated Hemoglobin (HbA1c) From Baseline to 26 Weeks in the Continuous Glucose Monitoring (CGM) and Control Groups (for the Cohort With Baseline HbA1c >=7.0%…
Phase 3 N=445 Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis. — 14.3; 66.4; 66.4 Percentage of Subjects…
Phase 3 N=451 Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis. — 14.3; 66.4; 64.5 Percentage of Subjects…
Phase 3 N=137 An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change in ASIiAUC During a Hyperglycemic Clamp Test. — 643.40; 686.41; 786.12; 747.26 uIU-min/ml — p=0.282